Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape.

Yu DM, Li XH, Mom V, Lu ZH, Liao XW, Han Y, Pichoud C, Gong QM, Zhang DH, Zhang Y, Deny P, Zoulim F, Zhang XX.

J Hepatol. 2014 Mar;60(3):515-22. doi: 10.1016/j.jhep.2013.11.004. Epub 2013 Nov 13.

PMID:
24239777
2.

Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.

Lavocat F, Dény P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F.

J Hepatol. 2013 Oct;59(4):684-95. doi: 10.1016/j.jhep.2013.05.038. Epub 2013 Jun 3.

PMID:
23742912
3.

High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.

Lacombe K, Boyd A, Lavocat F, Pichoud C, Gozlan J, Miailhes P, Lascoux-Combe C, Vernet G, Girard PM, Zoulim F.

Hepatology. 2013 Sep;58(3):912-22. doi: 10.1002/hep.26374. Epub 2013 Jun 25.

PMID:
23468093
4.

Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.

Billioud G, Pichoud C, Parent R, Zoulim F.

J Hepatol. 2012 Jun;56(6):1269-75. doi: 10.1016/j.jhep.2012.01.005. Epub 2012 Feb 4.

PMID:
22314422
5.

The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.

Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F.

Antiviral Res. 2011 Nov;92(2):271-6. doi: 10.1016/j.antiviral.2011.08.012. Epub 2011 Aug 18.

PMID:
21871497
6.

Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.

Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M.

Bone Marrow Transplant. 2011 Jan;46(1):125-31. doi: 10.1038/bmt.2010.70. Epub 2010 Apr 12.

PMID:
20383209
7.

Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D'Heuvaert N, Celis L, Doutreloigne J, Sablon E.

Antimicrob Agents Chemother. 2010 Mar;54(3):1283-9. doi: 10.1128/AAC.00970-09. Epub 2010 Jan 11.

8.

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.

Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F.

Gastroenterology. 2009 Jan;136(1):168-176.e2. doi: 10.1053/j.gastro.2008.09.068. Epub 2008 Oct 7.

PMID:
18996386
9.

Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.

Carrouée-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, Trépo C, Zoulim F.

Antivir Ther. 2008;13(3):381-8.

PMID:
18572751
10.

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F.

J Hepatol. 2008 May;48(5):747-55. doi: 10.1016/j.jhep.2008.01.027. Epub 2008 Feb 25.

PMID:
18331765
11.

Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections.

Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F.

J Clin Microbiol. 2007 Dec;45(12):3948-53. Epub 2007 Oct 17.

12.

Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion.

Li K, Zoulim F, Pichoud C, Kwei K, Villet S, Wands J, Li J, Tong S.

J Virol. 2007 Sep;81(17):9202-15. Epub 2007 Jun 13.

13.

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F.

J Hepatol. 2007 Mar;46(3):531-8. Epub 2006 Dec 18.

PMID:
17239478
14.

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F.

Gastroenterology. 2006 Oct;131(4):1253-61. Epub 2006 Aug 16.

PMID:
17030194
15.

European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.

Tran N, Berne R, Chann R, Gauthier M, Martin D, Armand MA, Ollivet A, Teo CG, Ijaz S, Flichman D, Brunetto M, Bielawski KP, Pichoud C, Zoulim F, Vernet G.

J Clin Microbiol. 2006 Aug;44(8):2792-800.

16.

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F.

Antimicrob Agents Chemother. 2006 Mar;50(3):955-61.

17.

Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing.

Durantel D, Brunelle MN, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F.

J Clin Virol. 2005 Dec;34 Suppl 1:S34-43. Review.

PMID:
16461221
18.

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F.

Hepatology. 2005 Jun;41(6):1391-8.

PMID:
15915463
19.

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

Durantel D, Carrouée-Durantel S, Werle-Lapostolle B, Brunelle MN, Pichoud C, Trépo C, Zoulim F.

Hepatology. 2004 Oct;40(4):855-64.

PMID:
15382118
20.

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.

Jacquard AC, Nassal M, Pichoud C, Ren S, Schultz U, Guerret S, Chevallier M, Werle B, Peyrol S, Jamard C, Rimsky LT, Trepo C, Zoulim F.

Antimicrob Agents Chemother. 2004 Jul;48(7):2683-92.

21.

Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.

Zoulim F, Berthillon P, Guerhier FL, Seigneres B, Germon S, Pichoud C, Cheng YC, Trepo C.

J Gastroenterol Hepatol. 2002 Dec;17 Suppl:S460-3.

PMID:
12534778
22.

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.

Seignères B, Pichoud C, Martin P, Furman P, Trépo C, Zoulim F.

Hepatology. 2002 Sep;36(3):710-22.

PMID:
12198665
23.

Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection.

Wartelle-Bladou C, Lafon J, Trépo C, Pichoud C, Picon M, Pellissier JF, Zoulim F.

J Hepatol. 2001 May;34(5):774-9.

PMID:
11434628
24.

Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.

Le Guerhier F, Pichoud C, Jamard C, Guerret S, Chevallier M, Peyrol S, Hantz O, King I, Trépo C, Cheng YC, Zoulim F.

Antimicrob Agents Chemother. 2001 Apr;45(4):1065-77.

25.

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

Seignères B, Aguesse-Germon S, Pichoud C, Vuillermoz I, Jamard C, Trépo C, Zoulim F.

J Hepatol. 2001 Jan;34(1):114-22.

PMID:
11211887
26.

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C, Zoulim F.

Hepatology. 2000 Nov;32(5):1078-88.

PMID:
11050059
27.

Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity.

Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, Trépo C, Zoulim F.

J Hepatol. 2000 Sep;33(3):430-9.

PMID:
11019999
28.

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

Seignères B, Pichoud C, Ahmed SS, Hantz O, Trépo C, Zoulim F.

J Infect Dis. 2000 Apr;181(4):1221-33. Epub 2000 Apr 13.

PMID:
10762559
29.

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B.

Pichoud C, Berby F, Stuyver L, Petit MA, Trépo C, Zoulim F.

J Hepatol. 2000 Feb;32(2):307-16.

PMID:
10707872
30.

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trépo C, Cheng YC, Zoulim F.

Antimicrob Agents Chemother. 2000 Jan;44(1):111-22.

31.

[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B].

Romand F, Michallet M, Pichoud C, Trépo C, Zoulim F.

Gastroenterol Clin Biol. 1999 Jun-Jul;23(6-7):770-4. French.

32.
33.

Analysis of a hepatitis delta virus isolate from the Central African Republic.

Langon T, Fillon S, Pichoud C, Hantz O, Trépo C, Kay A.

Res Virol. 1998 May-Jun;149(3):171-85.

PMID:
9711541
34.

Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.

Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, Chu CK, Trépo C, Cheng YC, Zoulim F.

Antimicrob Agents Chemother. 1998 Feb;42(2):369-76.

35.

A novel vector for the study of hepatitis delta virus replication.

Langon T, Pichoud C, Hantz O, Trépo C, Kay A.

J Virol Methods. 1998 Jan;70(1):19-28.

PMID:
9506809
36.
37.

[Treatment of hepatitis C].

Trepo C, Habersetzer F, Bailly F, Berby F, Pichoud C, Berthillon P, Vitvitski L.

Pathol Biol (Paris). 1995 Oct;43(8):716-24. Review. French.

PMID:
8745594
38.

Serial transmission of spongiocytic hepatitis to woodchucks (possible association with a specific delta strain).

Parana R, Gerard F, Lesbordes JL, Pichoud C, Vitvitski L, Lyra LG, Trepo C.

J Hepatol. 1995 Apr;22(4):468-73.

PMID:
7665865
39.

Hepatitis B, C, and D virus infections in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma: a comparative study in Niger.

Cenac A, Pedroso ML, Djibo A, Develoux M, Pichoud C, Lamothe F, Trepo C, Warter A.

Am J Trop Med Hyg. 1995 Apr;52(4):293-6.

PMID:
7537942
40.

Interferon therapy for hepatitis C.

Trépo C, Habersetzer F, Bailly F, Berby F, Pichoud C, Berthillon P, Vitvitski L.

Antiviral Res. 1994 Jul;24(2-3):155-63. Review.

PMID:
7979315
41.

Direct cloning and expression of PCR amplified DNA and RNA sequences: application to the hepadnaviruses nucleocapsid proteins.

Baginski I, Chemin I, Turin F, Pichoud C, Trépo C, Hantz O.

J Virol Methods. 1993 May;42(2-3):337-44.

PMID:
8514845
42.

Diagnostic markers of viral hepatitis B and C.

Trépo C, Zoulim F, Alonso C, Petit MA, Pichoud C, Vitvitski L.

Gut. 1993;34(2 Suppl):S20-5. Review.

43.

New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection.

Zoulim F, Mimms L, Floreani M, Pichoud C, Chemin I, Kay A, Vitvitski L, Trepo C.

J Clin Microbiol. 1992 May;30(5):1111-9.

44.

Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis.

Baginski I, Chemin I, Hantz O, Pichoud C, Jullien AM, Chevre JC, Li JS, Vitvitski L, Sninsky JJ, Trepo C.

Transfusion. 1992 Mar-Apr;32(3):215-20.

PMID:
1557801
45.

Lack of pre-C region mutation in woodchuck hepatitis virus from seroconverted woodchucks.

Tong SP, Vitvitski L, Li JS, Pichoud C, Trépo C.

Arch Virol Suppl. 1992;4:95-6.

PMID:
1450731
46.

Functional epitope analysis of the human CD11a/CD18 molecule (LFA-1, lymphocyte function-associated antigen 1) involved in HIV-1-induced syncytium formation.

Vermot-Desroches C, Rigal D, Escaich S, Bernaud J, Pichoud C, Lamelin JP, Trepo C.

Scand J Immunol. 1991 Oct;34(4):461-70.

PMID:
1718027
47.

Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection.

Zoulim F, Vitvitski L, Bouffard P, Pichoud C, Rougier P, Lamelin JP, Trépo C.

J Hepatol. 1991 Mar;12(2):150-6.

PMID:
1711065
48.

Correlation between HBV DNA detection by polymerase chain reaction and Pre-S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections.

Chemin I, Baginski I, Petit MA, Zoulim F, Pichoud C, Capel F, Hantz O, Trepo C.

J Med Virol. 1991 Jan;33(1):51-7.

PMID:
2016601
49.

Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection.

Vitvitski-Trépo L, Kay A, Pichoud C, Chevallier P, de Dinechin S, Shamoon BM, Mandart E, Trépo C, Galibert F.

Hepatology. 1990 Dec;12(6):1278-83.

PMID:
2258144
50.

Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B.

Bouffard P, Lamelin JP, Zoulim F, Pichoud C, Trepo C.

J Med Virol. 1990 Aug;31(4):312-7.

PMID:
2269882

Supplemental Content

Loading ...
Support Center